Biotech News

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Jaguar Health (JAGX)Jaguar Health2026-07-22 13:00 ESTCompany update

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc.

Related news

JAGXJaguar Health2026-09-10 13:00 EST

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

JAGXJaguar Health2026-09-04 12:30 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

IBRXImmunityBio2026-03-09 11:30 EST

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

SCYXSCYNEXIS2026-06-30 12:00 EST

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

HROWHarrow, Inc.2026-06-10 11:00 EST

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

ALZNAlzamend Neuro2025-05-29 12:00 EST

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZNAlzamend Neuro2025-05-19 12:00 EST

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

View all latest news

Jaguar Health

Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine...

Recent company news

JAGXJaguar Health2026-11-06 21:15 EST

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-11-02 14:00 EST

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

JAGXJaguar Health2026-10-21 13:00 EST

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

JAGXJaguar Health2026-10-14 20:15 EST

Jaguar Health Provides Update Regarding Special Stock Dividend

JAGXJaguar Health2026-10-14 13:00 EST

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Stock data

Close: 0.41 USD
Market cap: 2.12M USD
Exchange: NASDAQ
Sector: Biopharma
Location: San Francisco, California